Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Updates
            3Q19 Galafold ® (migalastat) Revenue of $48 .8M   and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Reiterating Upwardly Revised FY19 Revenue Guidance of $170M-$180M Complete Enrollment of 120+ Patients in AT-GAA Pompe Pivotal Study on Track by YE19 Continued
View HTML
Toggle Summary Amicus Therapeutics to Announce Third Quarter 2019 Financial Results on November 11, 2019
CRANBURY, N.J. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 11, 2019 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2019 .
View HTML
Toggle Summary Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Society
New Data Support Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment CRANBURY, N.J. , and CHARLOTTE, N.C. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics
View HTML
Toggle Summary Amicus Therapeutics Announces Preliminary Third Quarter 2019 Revenue and Financial Outlook at 2019 Analyst Day
Analyst Day 2019 to Highlight Financial Outlook and Robust Portfolio of Novel Therapies for Rare Metabolic Diseases 3Q19 Galafold ® (migalastat) Preliminary Unaudited Revenue of ~$48M+   and 1,000+ Patients on Therapy Reflects Continued Strong Global Uptake Company Raises Lower End of FY19 Global
View HTML
Toggle Summary Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study of AT-GAA at the 24th International Annual Congress of the World Muscle Society
Persistent and Durable Responses Across Safety, Functional Outcomes and Biomarkers for ERT-Naïve and ERT-Switch Patients in Cohorts 1, 2 and 3 Out to Month 24 Data in Additional Switch Patients (Cohort 4) Consistent with Reponses in Previous Cohorts Demonstrating Improvements in Multiple Measures
View HTML
Toggle Summary Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019
CRANBURY, N.J. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following medical and investor conferences in October. Upcoming Medical Conferences:     An oral presentation highlighting Phase 1/2 results, including cohort 4, for
View HTML
Toggle Summary Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019
CRANBURY, N.J. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at the following investor conferences in September. Bradley Campbell , President and Chief Operating Officer, and Jeff Castelli , Chief Portfolio Officer and Head of Gene
View HTML
Toggle Summary Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates
            2Q19 Galafold ® (migalastat) Revenue of $44.1M Represents Highest Quarterly  Growth Since Launch Driven by Continued Strong Global Uptake  Reiterating FY19 Revenue Guidance of $160M-$180M Full Enrollment in Pompe Pivotal Study of AT-GAA on Track by YE19 Significant Progress Across
View HTML
Toggle Summary Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina
          First Oral Precision Medicine Approved for People Living with Fabry Disease with an Amenable Mutation in Argentina First Amicus Regulatory Approval in Latin America CRANBURY, N.J. , and BUENOS AIRES, Argentina , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today
View HTML
Toggle Summary Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease
 Study Shows Meaningful Impact on Motor and Language Function in Children with Fatal Neurologic Disease Evidence of Disease Stabilization in 7 of 8 Children with Data for up to 2 Years Post-Treatment Conference Call at 8:30 a.m. ET Today CRANBURY, N.J. , Aug.
View HTML